OliX Pharmaceuticals Resubmits New Zealand Trial Application After Ethics Rejection; Shares Fall 5.72%

OliX Pharmaceuticals has resubmitted its New Zealand trial application for OLX301A after the local ethics committee rejected it over administrative matters, the company confirmed. The Korean biotech's shares closed at 90,600 won, down 5.72%, according to Naver.

OliX Resubmits OLX301A Application After Ethics Rejection

OliX Pharmaceuticals is a clinical-stage Korean biopharmaceutical company developing RNA interference therapeutics on its proprietary asymmetric siRNA platform for dermatology, ophthalmology and metabolic disease, and licensing its pipeline to partners including Eli Lilly and L'Oréal. Its OLX301A candidate is an siRNA-based therapy for macular degeneration. After a U.S. Phase 1 trial, OliX plans a Phase 2a study in patients with geographic atrophy, a condition involving progressive retinal tissue loss.

On October 12, OliX disclosed that New Zealand's ethics committee had rejected the application because its submissions did not meet local ethical and legal requirements. The company said the decision was separate from Medsafe's regulatory review. "The application was rejected over administrative matters requiring additional documentation following the local ethics committee's recommendations," an OliX official said. "We recently completed the resubmission." OliX now awaits another ethics decision.

The company also awaits the clinical study report for OLX702A, its MASH and obesity candidate licensed to Eli Lilly and Co. The Australian multiple-dose Phase 1 trial completed its final patient visit in May. "We expect the CSR by year-end, with no schedule changes at present," the official said. Interim findings disclosed earlier showed liver fat falling more than 70% in one participant, with some reaching levels below 5% within one to two months. These were preliminary findings, not final topline results. OliX must complete Phase 1, while Lilly handles subsequent development.

OliX's June Funding and L'Oréal Collaboration

According to akta.pro company records, OliX raised approximately KRW 110 billion (~$81 million) in June 2026 through a third-party allotment of common shares led by BOLD, L'Oréal's corporate venture capital fund, with participation from Weiss Asset Management LP. The same records show the company signed an expanded pipeline collaboration framework agreement with L'Oréal covering multiple siRNA programs in skin, hair and nail health. OliX's pipeline includes OLX301A for AMD, which completed Phase 1 in the U.S., and OLX702A for MASH, in Phase 1 in Australia.

Earlier OliX Milestones Before the Resubmission

OliX announced preclinical data on July 30, 2026, showing its ALK7-targeting OLX501A achieved 29.2% visceral fat reduction at Day 49 in obese non-human primates, compared to 10.0% for a globally developed comparator and an 11.1% increase in the control group, Yahoo reported. In June 2026, OliX raised approximately KRW 110 billion through a strategic investment from BOLD and Weiss Asset Management via a third-party allotment of newly issued common shares, Global Cosmetics News reported. On October 14, 2026, OliX said it would hold an in-person investor relations briefing for individual shareholders on October 19, 2026, from 10:00 a.m. to 11:00 a.m. local time at its Seongnam, Gyeonggi Province offices, The future of trading reported.

What Comes Next for OliX

OliX awaits another ethics decision on its resubmitted OLX301A application. The company expects the clinical study report for OLX702A by year-end.